The exact mechanisms of amrinone’s cardiac effects are not well understood. It is thought the primary effects are due to its vasodilatory effects, thereby reducing both preload and afterload. Because it inhibits phosphodiesterase, it may directly stimulate cardiac contractility.
Inamrinone is considered a second line agent for the short-term management of CHF. It was originally called amrinone, but was changed to inamrinone presumably to avoid confusion with amiodarone.
劑量數字暫停提供：VetPro 的劑量改依 DRUGAPI 藥物資料庫對外的內容，DRUGAPI 目前不提供可直接計算的劑量。下方列出 DRUGAPI 的審查結論與劑量審查引用的來源；計算機可手動輸入劑量換算。
必須由獸醫確認物種、精確心血管診斷、血流動力狀態、共病、器官功能及同步藥物。 任何考慮使用都必須重新核對精確成品、給予方式、監測、停用規則及緊急處置。 犬與貓的研究數值只能留在各自實驗情境，不得跨物種、疾病狀態、成品或研究設計轉移。 在完整獸醫臨床契約與主審批准前，系統不得計算、開立、輸出或建立自動交互作用。
依出現頻率分組；嚴重副作用獨立列出，臨床上需立即辨識。